Apotheek Berckenbosch SRL
Apotheek Berckenbosch reported total assets of 652,803 € at the end of the 2025 financial year (annual accounts filed with the NBB on 05 Jul 2026).
The score of Apotheek Berckenbosch shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +25 % Total assets +23 %
Accounts of the company itself (not consolidated).
The full file covers 7 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Apotheek Berckenbosch's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 05 Jul 2026
- Year ended 31 Dec 2024filed on 29 Aug 2025
- Year ended 31 Dec 2023filed on 31 Aug 2024
- Year ended 31 Dec 2022filed on 30 Aug 2023
- Year ended 31 Dec 2021filed on 26 Aug 2022
Apotheek Berckenbosch's financial analysis
- Solvency14.5%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Apotheek Berckenbosch
Apotheek Berckenbosch's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0687.849.071
- VAT number
- BE0687849071
- Peppol
- Registered · 0208:0687849071 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 11 Jan 2018
- Registered office
- 3012 Leuven
- Latest accounts
- 2025 · filed on 05 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Apotheek Berckenbosch (SRL) has been based in Leuven since 2018, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 11,969 € and equity of 94,866 €; its revenue is not published. Its solvency stands at 14.5%, below the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Apotheek Berckenbosch
Companies in the same business, of comparable size and area, outside its group.
- Raf BEX Retail sale of pharmaceutical products Leuven · balance sheet 651,970 €
- Pharmacie de Cherain Retail sale of pharmaceutical products Gouvy · balance sheet 658,226 €
- T.Lamote Retail sale of pharmaceutical products Merchtem · balance sheet 663,074 €
- Humbeek Pharma Retail sale of pharmaceutical products Grimbergen · balance sheet 653,604 €
- Apoteek Staes Retail sale of pharmaceutical products Diest · balance sheet 650,270 €
- Daluphar Retail sale of pharmaceutical products Anderlecht · balance sheet 651,365 €
- Curavaleas Retail sale of pharmaceutical products Antwerp · balance sheet 650,626 €
- Geva Pharma Retail sale of pharmaceutical products Oudenaarde · balance sheet 655,182 €
Frequently asked questions about Apotheek Berckenbosch
What is the revenue of Apotheek Berckenbosch?
Apotheek Berckenbosch files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Apotheek Berckenbosch?
In Belgium, the VAT number is the company number prefixed with BE: BE0687849071 for Apotheek Berckenbosch, if the company is VAT-registered. Its company number (CBE) is 0687.849.071.
Where is the registered office of Apotheek Berckenbosch?
According to the CBE register, the registered office of Apotheek Berckenbosch is in 3012 Leuven.
What is the equity of Apotheek Berckenbosch?
At the close of the 2025 financial year, the equity of Apotheek Berckenbosch amounts to 94,866 €, a solvency of 14.5% of total assets.
Who manages Apotheek Berckenbosch?
The register lists 1 active mandates at Apotheek Berckenbosch. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Apotheek Berckenbosch
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →